

DAFTAR PUSTAKA

- Agúndez, J.A.G., Ayuso, P., Cornejo-García, J.A., Blanca, M., Torres, M.J., Doña, I., Salas, M., Blanca-López, N., Canto, G., Rondon, C., Campo, P., Laguna, J.J., Fernández, J., Martínez, C., and García-Martín, E., 2012, the diamine oxidase gene is associated with hypersensitivity response to non-steroidal anti-inflammatory drugs., *PLoS One*, 7, 1–8.
- Albassam, H., Almutairi, O., Alnasser, M., Altowairqi, F., Almutairi, F., and Alobid, S., 2025, Discovery of a selective PI3K α inhibitor via structure-based virtual screening for targeted colorectal cancer therapy, *J. Enzyme Inhib. Med. Chem.*, 40, 2468852.
- Alkhateeb, M.A., Aljarba, N.H., Yousafi, Q., Anwar, F., and Biswas, P., 2024, Elucidating gastric cancer mechanisms and therapeutic potential of Adociaquinone A targeting EGFR: A genomic analysis and Computer Aided Drug Design (CADD) approach, *J. Cell. Mol. Med.*, 28, e70133.
- Allen, M.P., 2004, introduction to molecular dynamics simulation., *Comput. Soft Matter*, 23, 1–28.
- Alvarez, J. and Shoichet, B., 2005, virtual screening in drug discovery., Taylor & Francis, Boca Raton.
- Andaloussi, M., Lim, H.D., Van Der Meer, T., Sijm, M., Poulie, C.B.M., De Esch, I.J.P., Leurs, R., and Smits, R.A., 2013, a novel series of histamine H 4 receptor antagonists based on the pyrido[3,2-d]pyrimidine scaffold: Comparison of hERG binding and target residence time with PF-3893787., *Bioorganic Med. Chem. Lett.*, 23, 1–8.
- Balogh, B., Jójárt, B., Wágner, Z., Kovács, P., Máté, G., Gyires, K., Zádori, Z., Falkay, G., Márki, Á., Viskolcz, B., and Mátyus, P., 2007, 3D QSAR models for α 2a-adrenoceptor agonists., *Neurochem. Int.*, 51, 1–9.
- Becker, O.M., MacKerell, A.D., Roux, J.B., and Watanabe, M., 2001, computational biochemistry and biophysics., Marcel Dekker, Inc., New York.
- Best, C.G., Dale, H.H., Dudley, H.W., and Thrope, W. V., 1927, the nature of the vaso-dilator constituents of certain tissue extracts., *Natl. Inst. Med. Res.*, 1–21.
- Bielska, E., Lucas, X., Czerwoniec, A., Kasprzak, J.M., Kaminska, K.H., and Bujnicki, J.M., 2011, virtual screening strategies in drug design - methods and applications., *Biotechnologia*, 92, 2–16.
- Blandina, P. and Passani, M.B., 2016, histamine receptors: preclinical and clinical aspects., Springer Nature, Switzerland.
- Brown, E.D. and Wright, G.D., 2016, antibacterial drug discovery in the resistance era., *Nature*, 529, 1–8.
- Bruice, P.Y., 2016, organic chemistry., Pearson Education, California.
- Buckland, K.F., Williams, T.J., and Conroy, D.M., 2003, histamine induces cytoskeletal changes in human eosinophils via the H4 receptor., *Br. J. Pharmacol.*, 140, 1–11.
- Cai, W.K., Zhang, Jia Bin, Chen, J.H., Meng, J.R., Ma, X., Zhang, Juan, Zhou, Y.L., Xu, G.L., and He, G.H., 2017, the hRH4 rs11662595 mutation is associated with histamine H4 receptor dysfunction and with increased

- epithelial-to-mesenchymal transition progress in non-small cell lung cancer., *Biochim. Biophys. Acta - Mol. Basis Dis.*, 1863, 1–10.
- Cavasotto, C.N. and Orry, A.J.W., 2007, ligand docking and virtual screening in structure-based drug discovery., *Curr. Top. Med. Chem.*, 7, 1006–1014.
- Chen, J., Liu, C., and Lovenberg, T.W., 2003, molecular and pharmacological characterization of the mouse histamine H3 receptor., *Eur. J. Pharmacol.*, 467, 1–9.
- Cheng, T., Li, Q., Zhou, Z., Wang, Y., and Bryant, S.H., 2012, structure-based virtual screening for drug discovery: A problem-centric review., *AAPS J.*, 14, 1–9.
- Conrad, M., Söldner, C.A., Miao, Y., and Sticht, H., 2020, Agonist binding and G protein coupling in histamine h2 receptor: A molecular dynamics study, *Int. J. Mol. Sci.*, 21, 1–18.
- Corrêa, M.F., Balico-Silva, A.L., Kiss, D.J., Fernandes, G.A.B., Maraschin, J.C., Parreiras-e-Silva, L.T., Varela, M.T., Simões, S.C., Bouvier, M., Keserü, G.M., Costa-Neto, C.M., and Fernandes, J.P.S., 2021, Novel potent (dihydro)benzofuranyl piperazines as human histamine receptor ligands – Functional characterization and modeling studies on H3 and H4 receptors, *Bioorganic Med. Chem.*, 30, .
- Corrêa, M.F. and Fernandes, J.P.D.S., 2014, histamine H4 receptor ligands: Future applications and state of art., *Chem. Biol. Drug Des.*, 85, 1–20.
- Cortés-Benítez, F., Roy, J., Perreault, M., Maltais, R., and Poirier, D., 2021, 16-picolyl-androsterone derivative exhibits potent 17 β -HSD3 inhibitory activity, improved metabolic stability and cytotoxic effect on various cancer cells: Synthesis, homology modeling and docking studies., *J. Steroid Biochem. Mol. Biol.*, 210, 1–13.
- Coudert, E., Gehant, S., de Castro, E., Pozzato, M., Baratin, D., Neto, T., Sigrist, C.J.A., Redaschi, N., and Bridge, A., 2023, Annotation of biologically relevant ligands in UniProtKB using ChEBI, *Bioinformatics*, 39, .
- Deiteren, A., De Man, J.G., Pelckmans, P.A., and De Winter, B.Y., 2015, histamine H4 receptors in the gastrointestinal tract., *Br. J. Pharmacol.*, 172, 1–14.
- Deml, K.-F., Beermann, S., Neumann, D., Strasser, A., and Seifert, R., 2009, interactions of histamine H1-receptor agonists and antagonists with the human histamine H4-receptor., *Mol. Pharmacol.*, 76, 1–12.
- Dixon, D.A., 2018, Ab Initio Calculations, Springer International Publishing AG, Tuscaloosa, AL, USA.
- Durante, M., Sgambellone, S., Lanzi, C., Nardini, P., Pini, A., Moroni, F., Masini, E., and Lucarini, L., 2019, effects of PARP-1 deficiency and histamine H4receptor inhibition in an inflammatory model of lung fibrosis in mice., *Front. Pharmacol.*, 10, 1–13.
- Eckert, H. and Bajorath, J., 2007, molecular similarity analysis in virtual screening: foundations, limitations and novel approaches., *Drug Discov. Today*, 12, 1–9.
- Eissa, I.H., Yousef, R.G., Asmaey, M.A., Elkady, H., Husein, D.Z., Alsouk, A.A., Ibrahim, I.M., Elkady, M.A., Elkaeed, E.B., and Metwaly, A.M., 2023, Computer-assisted drug discovery (CADD) of an anti-cancer derivative of the theobromine alkaloid inhibiting VEGFR-2, *Saudi Pharm. J.*, 31, 101852.

- Ekins, S., Mestres, J., and Testa, B., 2007, in silico pharmacology for drug discovery: Applications to targets and beyond., *Br. J. Pharmacol.*, 152, 1–17.
- Feng, Z., Hou, T., and Li, Y., 2013, docking and MD study of histamine H4R based on the crystal structure of H1R., *J. Mol. Graph. Model.*, 39, 1–12.
- Ferreira, L.G., Dos Santos, R.N., Oliva, G., and Andricopulo, A.D., 2015, molecular docking and structure-based drug design strategies.,
- Ferreira, R.S., Guido, R.V., Andricopulo, A.D., and Oliva, G., 2011, in silico screening strategies for novel inhibitors of parasitic diseases., *Expert Opin. Drug Discov.*, 6, 1–9.
- Finlay, D.B., Duffull, S.B., and Glass, M., 2020, 100 years of modelling ligand–receptor binding and response: A focus on GPCRs, *Br. J. Pharmacol.*, 177, 1472–1484.
- Galal, N., Beshay, B.Y., Soliman, O., Ismail, M.I., Abdelfadil, M., El-Hadidi, M., Arafa, R.K., and Ibrahim, T.M., 2025, Evaluating the structure-based virtual screening performance of SARS-CoV-2 main protease: A benchmarking approach and a multistage screening example against the wild-type and Omicron variants., *PLoS One*, 20, e0318712.
- García Sánchez, N., Ugarte Carro, E., Prieto-Santamaría, L., and Rodríguez-González, A., 2024, Protein sequence analysis in the context of drug repurposing, *BMC Med. Inform. Decis. Mak.*, 24, 1–14.
- Gaulton, A., Bellis, L.J., Bento, A.P., Chambers, J., Davies, M., Hersey, A., Light, Y., McGlinchey, S., Michalovich, D., Al-Lazikani, B., and Overington, J.P., 2012, ChEMBL: A large-scale bioactivity database for drug discovery., *Nucleic Acids Res.*, 40, 1–8.
- Gerry Nugraha, Suprayetno, and Pangestu, D.R., 2022, Validasi Internal Kompleks Reseptor HMG-Coa Reduktase (Pdb:1hwk)-Atorvastatin Sebagai Antikolesterol dengan Metode Penambatan Ulang, 14, 172–183.
- Ghosh, S., Nie, A., An, J., and Huang, Z., 2006, structure-based virtual screening of chemical libraries for drug discovery., *Curr. Opin. Chem. Biol.*, 10, 1–9.
- Glatzer, F., Gschwandtner, M., Ehling, S., Rossbach, K., Janik, K., Wolfgang, B., Kietzmann, M., Werfel, T., Klos, A., and Gutzmer, R., 2013, histamine induces proliferation in keratinocytes from patients with atopic dermatitis through the histamine 4 receptor., *Am. Acad. Allergy, Asthma Immunol.*, 132, 1–10.
- De Graaf, C., Kooistra, A.J., Vischer, H.F., Katritch, V., Kuijter, M., Shiroishi, M., Iwata, S., Shimamura, T., Stevens, R.C., De Esch, I.J.P., and Leurs, R., 2011, crystal structure-based virtual screening for fragment-like ligands of the human histamine H1 receptor., *J. Med. Chem.*, 54, 1–15.
- Guido, R.V.C., Oliva, G., and Andricopulo, A.D., 2008, virtual screening and its integration with modern drug design technologies., *Curr. Med. Chem.*, 15, 1–11.
- Guillot-Sestier, M.V., Doty, K.R., and Town, T., 2015, innate immunity fights alzheimer’s disease., *Trends Neurosci.*, 38, 1–8.
- Gulania, S. and Whitfield, J.D., 2021, Limitations of Hartree-Fock with quantum resources, *J. Chem. Phys.*, 154, .
- Gutzmer, R., Gschwandtner, M., Rossbach, K., Mommert, S., Werfel, T.,

- Kietzmann, M., and Baeumer, W., 2011, pathogenetic and therapeutic implications of the histamine H4 receptor in inflammatory skin diseases and pruritus., *Front. Biosci. - Sch.*, 1–10.
- Haas, H. and Panula, P., 2003, the role of histamine and the tuberomammillary nucleus in the nervous system., *Nat. Rev. Neurosci.*, 4, 1–10.
- Harmita, Harahap, Y., and Hayun, 2008, buku ajar kimia medisinal., Departemen Farmasi FMIPA UI, Depok.
- Haryadi, W. and Pranowo, H.D., 2023, Molecular docking and dynamics analysis of halogenated imidazole chalcone as anticancer compounds, *Pharmacia*, 70, 323–329.
- Hawkins, P. and Skillman, G., 2006, ligand-based design work flow., *OpenEye Sci.*, 1–17.
- Heo, L., Arbour, C.F., Janson, G., and Feig, M., 2021, Improved Sampling Strategies for Protein Model Refinement Based on Molecular Dynamics Simulation, *J. Chem. Theory Comput.*, 17, 1931–1943.
- Hermawan, F., Jumina, J., Pranowo, H.D., Ernawati, T., Kurniawan, Y.S., and Zikri, A.T., 2024, In-silico Studies of Epoxy-Thioxanthone Derivatives as Potential Tyrosine Kinase Inhibitor Using Molecular Docking, Molecular Dynamics Simulations, MM-PBSA and ADMET, *Brazilian J. Pharm. Sci.*, 60, 1–17.
- Hinchliffe, A., 2008, molecular modelling for beginners, Second. John Wiley & Sons Ltd, Weinheim, Germany.
- Hollingsworth, S.A. and Dror, R.O., 2018, Molecular Dynamics Simulation for All, *Neuron*, 99, 1129–1143.
- Holtje, H.D., Folkers, G., and Luzar, A., 1998, molecular modeling, basic principles and applications.,
- Hou, T. and Xu, X., 2004, Recent Development and Application of Virtual Screening in Drug Discovery: An Overview, *Front. Med. Chem. - (Volume 3)*, 10, 675–703.
- Hough, L.B., 2001, genomics meets histamine receptors: New subtypes, new receptors., *Mol. Pharmacol.*, 59, 1–5.
- Huang, N., Shoichet, B.K., and Irwin, J.J., 2006, benchmarking sets for molecular docking., *J. Med. Chem.*, 49, 1–13.
- Ihsan, M.F. and Yanuar, A., 2018, molecular dynamics simulations of several selected compounds from the herbal database of Indonesia results of molecular docking against DNA methyltransferase enzyme, *Int. J. Appl. Pharm.*, 10, 1–6.
- Iqbal, M.A., Ashraf, N., Shahid, W., Afzal, D., Idrees, F., and Ahmad, R., 2021, Fundamentals of Density Functional Theory: Recent Developments, Challenges and Future Horizons, *Intech*, 1.
- Isberg, V., Mordalski, S., Munk, C., Rataj, K., Harpsøe, K., Hauser, A.S., Vroiling, B., Bojarski, A.J., Vriend, G., and Gloriam, D.E., 2016, GPCRdb: An information system for G protein-coupled receptors, *Nucleic Acids Res.*, 44, D356–D364.
- Istyastono, E.P., 2012, construction, validation and application of structure-based virtual screening protocols to discover new cyclooxygenase-2 inhibitors, *Indo.*

J. Chem, 12, 1–5.

- Istyastono, E.P., Kooistra, A.J., Vischer, H.F., Kuijer, M., Roumen, L., Nijmeijer, S., Smits, R.A., De Esch, I.J.P., Leurs, R., and De Graaf, C., 2015, structure-based virtual screening for fragment-like ligands of the G protein-coupled histamine H4 receptor., *Medchemcomm*, 6, 1–15.
- Istyastono, E.P., Nijmeijer, S., Lim, H.D., Van De Stolpe, A., Roumen, L., Kooistra, A.J., Vischer, H.F., De Esch, I.J.P., Leurs, R., and De Graaf, C., 2011, molecular determinants of ligand binding modes in the histamine H4 receptor: Linking ligand-based three-dimensional quantitative structure-activity relationship (3D-QSAR) models to in silico guided receptor mutagenesis studies., *J. Med. Chem.*, 54, 1–12.
- Istyastono, E.P., Radifar, M., Yuniarti, N., Prasasty, V.D., and Mungkasi, S., 2020, PyPLIF HIPPOS: A Molecular Interaction Fingerprinting Tool for Docking Results of AutoDock Vina and PLANTS, *J. Chem. Inf. Model.*, 60, 3697–3702.
- Jablonowski, J.A., Grice, C.A., Chai, W., Dvorak, C.A., Venable, J.D., Kwok, A.K., Ly, K.S., Wei, J., Baker, S.M., Desai, P.J., Jiang, W., Wilson, S.J., Thurmond, R.L., Karlsson, L., Edwards, J.P., Lovenberg, T.W., and Carruthers, N.I., 2003, the first potent and selective non-imidazole human histamine H4 receptor antagonists., *J. Med. Chem.*, 46, 1–4.
- Jarisch, R., 2015, histamin intolerance., Springer Heidelberg, New York.
- Jensen, F., 2017, introduction to computational chemistry computational chemistry., third edit. John Wiley & Sons, UK.
- Jiménez-Jiménez, F.J., Alonso-Navarro, H., García-Martín, E., and Agúndez, J.A.G., 2016, Thr105Ile (rs11558538) polymorphism in the histamine N - methyltransferase (HNMT) gene and risk for parkinson disease., *Medicine (Baltimore)*, 95, 1–8.
- Jochem, J., Altinbas, B., Yalcin, M., Ottani, A., Giuliani, D., Savci, V., Kasperska-Zajac, A., and Guarini, S., 2016, involvement of the histaminergic system in the resuscitating effect of centrallyacting leptin in haemorrhagic shock in rats., *J. Physiol. Pharmacol.*, 67, 1–8.
- Jórárt, B., Kiss, R., Viskolcz, B., and Keseru, G.M., 2008, activation mechanism of the human histamine H4 receptor - An explicit membrane molecular dynamics simulation study., *J. Chem. Inf. Model.*, 48, 1–12.
- Jones, D.T., 1999, protein secondary structure prediction based on position-specific scoring matrices, *J. Mol. Biol.*, 292, 1–8.
- Karplus, M. and Kuriyan, J., 2005, molecular dynamics and protein function., *Proc. Natl. Acad. Sci. U. S. A.*, 102, 1–7.
- Khanifah, F., Puspita Sari, E., and Nugraha, G., 2024, Stability of Serotonin Transporter Essential Amino Acid Complex with Curcumin and Demethoxycurcumin Compounds as Antidepressant Candidates Based on In Silico Test, *J. Pharmasci (Journal Pharm. Sci.)*, 9, 15–21.
- Kiss, R. and Keserü, G.M., 2016, structure-based discovery and binding site analysis of histamine receptor ligands., *Expert Opin. Drug Discov.*, 11, 1–20.
- Kiss, R., Noszál, B., Rácz, Á., Falus, A., Eros, D., and Keseru, G.M., 2008, binding mode analysis and enrichment studies on homology models of the human

- histamine H4 receptor., *Eur. J. Med. Chem.*, 43, 1–12.
- Kitchen, D.B., Decornez, H., Furr, J.R., and Bajorath, J., 2004, docking and scoring in virtual screening for drug discovery: methods and applications., *Nat. Rev. Drug Discov.*, 3, 1–15.
- Knapp, B., Frantal, S., Cibena, M., Schreiner, W., and Bauer, P., 2011, Is an intuitive convergence definition of molecular dynamics simulations solely based on the root mean square deviation possible?, *J. Comput. Biol.*, 18, 997–1005.
- Knox, C., Wilson, M., Klinger, C.M., Mark, F., Oler, E., Wilson, A., Pon, A., Cox, J., Eun, N., Chin, L., Str, S.A., Gar, M., Sanf, S., Doshi, R., Khetarpal, N., Fatokun, O., Doucet, D., Zubkowski, A., Rayat, D.Y., et al., 2024, DrugBank 6.0 : the DrugBank Knowledgebase for 2024, *Nucleic Acids Res.*, 52, 1265–1275.
- Kooistra, A.J., Mordalski, S., Pándy-Szekeres, G., Esguerra, M., Mamyrbekov, A., Munk, C., Keserú, G.M., and Gloriam, D.E., 2021, GPCRdb in 2021: Integrating GPCR sequence, structure and function, *Nucleic Acids Res.*, 49, D335–D343.
- Krieger, E., Joo, K., Lee, Jinwoo, Lee, Jooyoung, Raman, S., Thompson, J., Tyka, M., Baker, D., and Karplus, K., 2009, improving physical realism, stereochemistry and side-chain accuracy in homology modeling: four approaches that performed well in CASP8., *Proteins*, 77, 114–122.
- Kroemer, R.T., 2007, structure-based drug design: docking and scoring., *Curr. Protein Pept. Sci.*, 8, 1–18.
- Kržan, M., Keuschler, J., Mavri, J., and Vianello, R., 2020, Relevance of Hydrogen Bonds for the Histamine H2 Receptor-Ligand Interactions: A Lesson from Deuteration, *Biomolecules*, 10, 1–10.
- Kucher, A.N., 2019, association of polymorphic variants of key histamine metabolism genes and histamine receptor genes with multifactorial diseases., *Russ. J. Genet.*, 55, 1–21.
- Kumar, A., Pasam, V.R., Thakur, R.K., Singh, M., Singh, K., Shukla, M., Yadav, A., Dogra, S., Sona, C., Umrao, D., Jaiswal, S., Ahmad, H., Rashid, M., Singh, S.K., Wahajuddin, M., Dwivedi, A.K., Siddiqi, M.I., Lal, J., Tripathi, R.P., et al., 2019, novel tetrahydroquinazolinamines as selective histamine 3 receptor antagonists for the treatment of obesity., *J. Med. Chem.*, 62, 1–18.
- Kurniawan, Y.S., Amrulloh, H., Yudha, E., Fatmasari, N., Hermawan, F., Fitria, A., Pranowo, H.D., Sholikhah, E.N., and Jumina, J., 2025, Evaluation of Xanthone and Cinnamoylbenzene as Anticancer Agents for Breast Cancer Cell Lines through In Vitro and In Silico Assays, *J. Multidiscip. Appl. Nat. Sci.*, 5, 87–102.
- Kurniawan, Y.S., Yudha, E., Nugraha, G., Fatmasari, N., Pranowo, H.D., Jumina, J., and Sholikhah, E.N., 2024, Molecular Docking and Molecular Dynamic Investigations of Xanthone-Chalcone Derivatives against Epidermal Growth Factor Receptor for Preliminary Discovery of Novel Anticancer Agent, *Indones. J. Chem.*, 24, 250–266.
- Lamas, D.J.M., Rivera, E.S., and Medina, V.A., 2015, histamine H4 receptor: insights into a potential therapeutic target in breast cancer., *Front. Biosci.* -

Sch., 7, 1–9.

- Land, H. and Humble, M.S., 2018, YASARA: a tool to obtain structural guidance in biocatalytic investigations.. In, *Methods in Molecular Biology.*, pp. 43–66.
- Larson, R.S. and Oprea, T.I., 2019, bioinformatics and drug discovery., Third Edit. Humana Press, New York.
- Leach, A., 2001, molecular modelling: principles and applications-prentice hall., Second. Pearson Education Limited, England.
- Leach, A.R., Shoichet, B.K., and Peishoff, C.E., 2006, docking and scoring., *Am. Chem. Soc.*, 49, 1–5.
- Lengauer, T. and Rarey, M., 1996, computational methods for biomolecular docking., *Curr. Opin. Struct. Biol.*, 6, 1–5.
- Li, Z., Huang, R., Xia, M., Patterson, T.A., and Hong, H., 2024, Fingerprinting Interactions between Proteins and Ligands for Facilitating Machine Learning in Drug Discovery, *Biomolecules*, 14, .
- Lim, H.D., De Graaf, C., Jiang, W., Sadek, P., McGovern, P.M., Istyastono, E.P., Bakker, R.A., De Esch, I.J.P., Thurmond, R.L., and Leurs, R., 2010, molecular determinants of ligand binding to H4R species variants., *Mol. Pharmacol.*, 77, 1–10.
- Lipinski, C.A., Lombardo, F., Dominy, B.W., and Feeney, P.J., 2001, experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings., *Adv. Drug Deliv. Rev.*, 46, 1–24.
- Liu, J., Lin, S., Huynh, A., and Tan, W., 2024, Effects of H2-Receptor Antagonists on the Exposure of Dacomitinib, *Pharmaceutics*, 16, 1–17.
- Liu, K., Watanabe, E., and Kokubo, H., 2017, exploring the stability of ligand binding modes to proteins by molecular dynamics simulations, *J. Comput. Aided. Mol. Des.*, 31, 1–10.
- Lodish, H., Berk, A., Kaiser, C.A., Krieger, M., Bretscher, A., Ploegh, H., Amon, A., and Martin, K.C., 2016, molecular cell biology., 8th ed. W. H. Freeman and Company, New York.
- Marcou, G. and Rognan, D., 2007, optimizing fragment and scaffold docking by use of molecular interaction fingerprints., *J. Chem. Inf. Model.*, 47, 1–13.
- Marson, C.M., 2011, targeting the histamine H4 receptor., *Am. Chem. Soc.*, 111, 1–36.
- McGovern, S.L. and Shoichet, B.K., 2003, information decay in molecular docking screens against holo, apo, and modeled conformations of enzymes., *J. Med. Chem.*, 46, 1–12.
- Mehta, P., Misztal, P., Rzedkiewicz, P., Michalak, O., Krzeczyński, P., and Filipek, S., 2020, Enigmatic histamine receptor h4 for potential treatment of multiple inflammatory, autoimmune, and related diseases, *Life*, 10, .
- Melagraki, G. and Afantitis, A., 2011, ligand and structure based virtual screening strategies for hit-finding and optimization of hepatitis c virus (hcv) inhibitors., *Curr. Med. Chem.*, 18, 1–7.
- Meti, M.D., Nandibewoor, S.T., Joshi, S.D., More, U.A., and Chimatadar, S.A., 2015, multi-spectroscopic investigation of the binding interaction of fosfomycin with bovine serum albumin., *J. Pharm. Anal.*, 5, 1–7.
- Michinaga, S., Nagata, A., Ogami, R., Ogawa, Y., and Hishinuma, S., 2024,

- Histamine H1 Receptor-Mediated JNK Phosphorylation Is Regulated by Gq Protein-Dependent but Arrestin-Independent Pathways, *Int. J. Mol. Sci.*, 25, .
- Modi, V. and Dunbrack, R.L., 2016, Assessment of refinement of template-based models in CASP11, *Proteins Struct. Funct. Bioinforma.*, 84, 260–281.
- Muhith, A., Fitrah Dewi, R., Hidayati, N., Syawiril Ammah, E., Jauhari, J., and Fathkul Wahab, A., 2022, Pemanfaatan Obat Bahan Alam Untuk Menjaga Imunitas Tubuh Berdasarkan Kajian Etnobotani Dan Thibbun Nabawi, *Al-Hikmah J. Agama dan Ilmu Pengetah.*, 19, 85–94.
- Munk, C., Harpsøe, K., Hauser, A.S., Isberg, V., and Gloriam, D.E., 2016, Integrating structural and mutagenesis data to elucidate GPCR ligand binding, *Curr. Opin. Pharmacol.*, 30, 51–58.
- Munk, C., Mutt, E., Isberg, V., Nikolajsen, L.F., Bibbe, J.M., Flock, T., Hanson, M.A., Stevens, R.C., Deupi, X., and Gloriam, D.E., 2019, An online resource for GPCR structure determination and analysis, *Nat. Methods*, 16, 151–162.
- Murray, R.K., Bender, D.A., Botham, K.M., Kennelly, P.J., Rodwell, V.W., and Weil, P.A., 2009, harper's illustrated biochemistry., 28th ed. McGraw-Hill Companies, Inc., New York.
- Mysinger, M.M., Carchia, M., Irwin, J.J., and Shoichet, B.K., 2012, directory of useful decoys, enhanced (DUD-E): Better ligands and decoys for better benchmarking., *J. Med. Chem.*, 55, 1–13.
- Nelson, W.L., 2013, antihistamines and related antiallergic and antiulcer agents., In, *Foye's Principles of Medicinal Chemistry*. Lippincott Williams and Wilkins, Philadelphia, pp. 1–28.
- Neumann, D., 2016, role of the histamine H4-receptor in bronchial asthma., In, *Handbook of Experimental Pharmacology*. Springer International Publishing, Switzerland, pp. 1–13.
- Nicoud, M.B., Táquez Delgado, M.A., Sarasola, M. de la P., Vidal, A., Speisky, D., Cremaschi, G.A., Sterle, H.A., and Medina, V.A., 2021, Impact of histamine H4 receptor deficiency on the modulation of T cells in a murine breast cancer model, *Cancer Immunol. Immunother.*, 70, 233–244.
- Niu, Y. and Lin, P., 2023, Advances of computer-aided drug design (CADD) in the development of anti-Azheimer's-disease drugs, *Drug Discov. Today*, 28, 103665.
- Nugraha, G. and Istyastono, E.P., 2021, Virtual target construction for structure-based screening in the discovery of histamine h2 receptor ligands, *Int. J. Appl. Pharm.*, 13, 1–3.
- Nurhidayah, M., Fadilah, F., Arsianti, A., and Bahtiar, A., 2022, Identification of FGFR inhibitor as ST2 receptor/interleukin-1 receptor-like 1 inhibitor in chronic obstructive pulmonary disease due to exposure to e-cigarettes by network pharmacology and molecular docking prediction., *Int. J. Appl. Pharm.*, 14, 10.
- Oda, T., Morikawa, N., Saito, Y., Masuho, Y., and Matsumoto, S.I., 2000, molecular cloning and characterization of a novel type of histamine receptor preferentially expressed in leukocytes., *J. Biol. Chem.*, 275, 1–7.
- Pándy-Szekeres, G., Caroli, J., Mamyrbekov, A., Kermani, A.A., Keseru, G.M., Kooistra, A.J., and Gloriam, D.E., 2023, GPCRdb in 2023: state-specific

- structure models using AlphaFold2 and new ligand resources, *Nucleic Acids Res.*, 51, D395–D402.
- Panula, P., 2021, Histamine receptors, agonists, and antagonists in health and disease., In, *Handbook of Clinical Neurology.*, pp. 377–387.
- Parsons, M.E. and Ganellin, C.R., 2006, histamine and its receptors., *Br. J. Pharmacol.*, 147, 1–9.
- Periyasamy, T.S., Kasivishwanathan, A., Roy, G., Sekar, N., and Lakshmanan, H., 2025, Phytocompounds of *Senecio candicans* as potential acetylcholinesterase inhibitors targeting Alzheimer’s disease: A structure-based virtual screening and molecular dynamics simulation study, *Comput. Biol. Chem.*, 117, 108396.
- Perz, J.B. and Ho, A.D., 2008, histamine dihydrochloride for the treatment of acute myeloid leukemia, malignant melanoma and renal cell carcinoma., *Futur. Oncol.*, 4, 1–9.
- Pittenger, C., 2020, The histidine decarboxylase model of tic pathophysiology: a new focus on the histamine H3 receptor, *Br. J. Pharmacol.*, 177, 570–579.
- Pripp, A.H., 2007, docking and virtual screening of ACE inhibitory dipeptides., *Eur. Food Res. Technol.*, 225, 1–4.
- Provasi, D., Artacho, M.C., Negri, A., Mobarec, J.C., and Filizola, M., 2011, Ligand-Induced modulation of the Free-Energy landscape of G protein-coupled receptors explored by adaptive biasing techniques, *PLoS Comput. Biol.*, 7, .
- Radifar, M., Yuniarti, N., and Istyastono, E.P., 2013, PyPLIF: Python-based protein-ligand interaction fingerprinting., *Bioinformatics*, 9, 1–4.
- Ramachandran, K.I., Deepa, G., and Namboori, K., 2008, computational chemistry and molecular modeling: Principles and applications., Springer Berlin Heidelberg, Berlin.
- van Rijn, R.M., van Marle, A., Chazot, P.L., Langemeijer, E., Qin, Y., Shenton, F.C., Lim, H.D., Zuiderveld, O.P., Sansuk, K., Dy, M., Smit, M.J., Tensen, C.P., Bakker, R.A., and Leurs, R., 2008, cloning and characterization of dominant negative splice variants of the human histamine H4 receptor., *Biochem. J.*, 414, 1–13.
- Riley, J.F., 1953, histamine in tissue mast cells., *Science (80-)*, 118, 1–2.
- Rognan, D., 2012, Fragment-Based Approaches and Computer-Aided Drug Discovery.,
- Rosano, C., Lappano, R., F. Santolla, M., Ponassi, M., Donadini, A., and Maggiolini, M., 2012, recent advances in the rationale design of GPER ligands., *Curr. Med. Chem.*, 19, 1–8.
- Rusinko, A., Rezaei, M., Friedrich, L., Buchstaller, H.P., Kuhn, D., and Ghogare, A., 2024, AIDDISON: Empowering Drug Discovery with AI/ML and CADD Tools in a Secure, Web-Based SaaS Platform, *J. Chem. Inf. Model.*, 64, 3–8.
- Rutz, A., Sorokina, M., Galgonek, J., Mietchen, D., Willighagen, E., Gaudry, A., Graham, J.G., Stephan, R., Page, R., Vondrášek, J., Steinbeck, C., Pauli, G.F., Wolfender, J.L., Bisson, J., and Allard, P.M., 2022, The LOTUS initiative for open knowledge management in natural products research, *Elife*, 11, 1–41.
- Salahudeen, M.S. and Nishtala, P.S., 2017, An overview of pharmacodynamic modelling , ligand-binding approach and its application in clinical practice,

- Saudi Pharm. J.*, 25, 165–175.
- Salo-Ahen, O.M.H., Alanko, I., Bhadane, R., Bonvin, A.M.J.J., Honorato, R.V., Hossain, S., Juffer, A.H., Kabedev, A., Lahtela-Kakkonen, M., Larsen, A.S., Lescrinier, E., Marimuthu, P., Mirza, M.U., Mustafa, G., Nunes-Alves, A., Pantsar, T., Saadabadi, A., Singaravelu, K., and Vanmeert, and M., 2021, Molecular Dynamics Simulations in Drug Discovery and Pharmaceutical Development, *Processes*, 9, 1–60.
- Sánchez, R. and Šali, A., 1997, advances in comparative protein-structure modelling., *Curr. Opin. Struct. Biol.*, 7, 1–9.
- Sandhaus, S., Chapagain, P.P., and Tse-Dinh, Y.C., 2018, discovery of novel bacterial topoisomerase i inhibitors by use of in silico docking and in vitro assays., *Sci. Rep.*, 8, 1–9.
- Saravanan, C., K. Bharti, S., Jaggi, S., and K. Singh, S., 2011, histamine h4 receptor: a novel target for inflammation therapy., *Mini-Reviews Med. Chem.*, 11, 1–16.
- Schaper-Gerhardt, K., Rossbach, K., Nikolouli, E., Werfel, T., Gutzmer, R., and Mommert, S., 2020, The role of the histamine H4 receptor in atopic dermatitis and psoriasis, *Br. J. Pharmacol.*, 177, 490–502.
- Schirmer, B. and Neumann, D., 2021, The function of the histamine h4 receptor in inflammatory and inflammation-associated diseases of the gut, *Int. J. Mol. Sci.*, 22, .
- Schneider, E.H., Schnell, D., Papa, D., and Seifert, R., 2009, high constitutive activity and a G-protein-independent high-affinity state of the human histamine H4-receptor., *Biochemistry*, 48, 1–15.
- Schneider, E.H., Strasser, A., Thurmond, R.L., and Seifert, R., 2010, structural requirements for inverse agonism and neutral antagonism of indole-, benzimidazole-, and thienopyrrole-derived histamine H4 receptor ligands., *J. Pharmacol. Exp. Ther.*, 334, 1–9.
- Schneider, G., 2014, de novo molecular design., Wiley-VCH Verlag GmbH & Co., Weinheim, Germany.
- Schultes, S., Nijmeijer, S., Engelhardt, H., Kooistra, A.J., Vischer, H.F., De Esch, I.J.P., Haaksma, E.E.J., Leurs, R., and De Graaf, C., 2013, mapping histamine H4 receptor-ligand binding modes., *Medchemcomm*, 4, 1–12.
- Seifert, R., Schnell, D., Brunskole, I., Ladova, K., Schneider, E.H., Igel, P., Dove, S., and Buschauer, A., 2011, paradoxical stimulatory effects of the “standard” histamine h4-receptor antagonist JNJ7777120: the h4 receptor joins the club of 7 transmembrane domain receptors exhibiting functional selectivity., *Mol. Pharmacol.*, 79, 1–8.
- Shahid, M., Tripathi, T., Sobia, F., Moin, S., Siddiqui, M., and Khan, R.A., 2009, histamine, histamine receptors, and their role in immunomodulation: An updated systematic review., *Open Immunol. J.*, 2, 1–33.
- Shan, Y., Gao, Y., Zhang, L., Ma, L., Shi, Y., and Liu, X., 2019, H4 receptor inhibits lipopolysaccharide-induced nf-kb activation by interacting with tumor necrosis factor receptor-associated factor 6., *Neuroscience*, 398, 1–13.
- Sharma, A., Narang, A., Kumar, N., Rana, R., Megha, Pooja, Dhir, M., Gulati, H.K., Jyoti, Khanna, A., Singh, J.V., Kaur, S., and Bedi, P.M.S., 2025, CADD based

- designing and biological evaluation of novel triazole based thiazolidinedione coumarin hybrids as antidiabetic agent, *Sci. Rep.*, 15, 4302.
- Shimamura, T., Shiroishi, M., Weyand, S., Tsujimoto, H., Winter, G., Katritch, V., Abagyan, R., Cherezov, V., Liu, W., Han, G.W., Kobayashi, T., Stevens, R.C., and Iwata, S., 2011, structure of the human histamine H1 receptor complex with doxepin, *Nature*, 475, 1–8.
- Shin, N., Coates, E., Murgolo, N.J., Morse, K.L., Bayne, M., Strader, C.D., and Monsma, F.J., 2002, molecular modeling and site-specific mutagenesis of the histamine-binding site of the histamine H4 receptor., *Mol. Pharmacol.*, 62, 1–10.
- Sirci, F., Istyastono, E.P., Vischer, H.F., Kooistra, A.J., Nijmeijer, S., Kuijter, M., Wijtmans, M., Mannhold, R., Leurs, R., De Esch, I.J.P., and De Graaf, C., 2012, Subscriber access provided by UNIV OF CALGARY Virtual fragment screening: Discovery of histamine H 3 receptor ligands using ligand-based and protein-based molecular fingerprints,.
- Smits, R.A., Lim, H.D., Van Der Meer, T., Kuhne, S., Bessembinder, K., Zuiderveld, O.P., Wijtmans, M., De Esch, I.J.P., and Leurs, R., 2012, ligand based design of novel histamine H 4 receptor antagonists; Fragment optimization and analysis of binding kinetics., *Bioorganic Med. Chem. Lett.*, 22, 1–7.
- Sobral, P.S., Carvalho, T., Izadi, S., Castilho, A., Silva, Z., Videira, P.A., and Pereira, F., 2025, Advancements in drug discovery: integrating CADD tools and drug repurposing for PD-1/PD-L1 axis inhibition, *RSC Adv.*, 15, 2298–2316.
- Sousa, J.A., Silva, P.P., Machado, A.E.H., Reis, M.H.M., Romanielo, L.L., and Hori, C.E., 2013, application of computational chemistry methods to obtain thermodynamic data for hydrogen production from liquefied petroleum gas, *Brazilian J. Chem. Eng.*, 30, 1–11.
- Stasiak, A., Gola, J., Kraszewska, K., Mussur, M., Kobos, J., Mazurek, U., Stark, H., and Fogel, W.A., 2018, experimental autoimmune myocarditis in rats and therapeutic histamine H1 – H4 receptor inhibition., *J. Physiol. Pharmacol.*, 69, 1–12.
- Sterle, H.A., Nicoud, M.B., Massari, N.A., Táquez Delgado, M.A., Herrero Ducloux, M. V., Cremaschi, G.A., and Medina, V.A., 2018, immunomodulatory role of histamine H4 receptor in breast cancer., *Br. J. Cancer*, 120, 1–11.
- Stevenson, J., Sonuga-Barke, E., McCann, D., Grimshaw, K., Parker, K.M., Rose-Zerilli, M.J., Holloway, J.W., and Warner, J.O., 2010, the role of histamine degradation gene polymorphisms in moderating the effects of food additives on children’s ADHD symptoms., *Am J Psychiatry*, 167, 1–9.
- Strakhova, M.I., Nikkel, A.L., Manelli, A.M., Hsieh, G.C., Esbenshade, T.A., Brioni, J.D., Bitner, R.S., Road, A.P., and Park, A., 2009, localization of histamine H 4 receptors in the central nervous system of human and rat., *Brain Res.*, 1250, 1–8.
- Takahashi, Y., Kagawa, Y., Izawa, K., Ono, R., Akagi, M., and Kamei, C., 2009, effect of histamine H4 receptor antagonist on allergic rhinitis in mice., *Int.*

- Immunopharmacol.*, 9, 1–5.
- Tan, L., Geppert, H., Sisay, M.T., Gütschow, M., and Bajorath, J., 2008, integrating structure- and ligand-based virtual screening: Comparison of individual, parallel, and fused molecular docking and similarity search calculations on multiple targets., *ChemMedChem*, 3, 1–6.
- Taylor-Clark, T., 2010, histamine in allergic rhinitis., *Adv. Exp. Med. Biol.*, 709, 1–9.
- Teodoro, M.L., Phillips, J., and Kavraki, L.E., 2001, molecular docking: A problem with thousands of degrees of freedom., *Proc. - IEEE Int. Conf. Robot. Autom.*, 1, 1–6.
- Terzioglu, N., Van Rijn, R.M., Bakker, R.A., De Esch, I.J.P., and Leurs, R., 2004, synthesis and structure-activity relationships of indole and benzimidazole piperazines as histamine H 4 receptor antagonists., *Bioorganic Med. Chem. Lett.*, 14, 1–6.
- Thompson, J.D., 2000, DbClustal: rapid and reliable global multiple alignments of protein sequences detected by database searches., *Nucleic Acids Res.*, 28, 1–8.
- Thurmond, R.L., 2015, the histamine H4 receptor: From orphan to the clinic., *Front. Pharmacol.*, 6, 1–12.
- Thurmond, R.L., Gelfand, E.W., and Dunford, P.J., 2008, the role of histamine H1 and H4 receptors in allergic inflammation: The search for new antihistamines., *Nat. Rev. Drug Discov.*, 7, 1–13.
- Tiligada, E., Zampeli, E., Sander, K., Stark, H., Tiligada, E., Zampeli, E., Sander, K., and Stark, H., 2009, Histamine H 3 and H 4 receptors as novel drug targets Histamine H 3 and H 4 receptors as novel drug targets, *Expert Opin. Investig. Drugs*, 18, 1–15.
- Toledo, L., Masgrau, L., Maréchal, J.D., Lluch, J.M., and González-Lafont, Á., 2010, insights into the mechanism of binding of arachidonic acid to mammalian 15-lipoxygenases., *J. Phys. Chem. B*, 114, 1–10.
- Traiffort, E., Leurs, R., Arrang, J.M., Tardivel-Lacombe, J., Diaz, J., Schwartz, J. - C, and Ruat, M., 1994, guinea pig histamine H1 receptor. i. gene cloning, characterization, and tissue expression revealed by in situ hybridization., *J. Neurochem.*, 62, 1–12.
- Trott, O. and Olson, A.J., 2009, autodock vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading., *J. of Computational Chem.*, 31, 1–7.
- Venable, J.D., Cai, H., Chai, W., Dvorak, C.A., Grice, C.A., Jablonowski, J.A., Shah, C.R., Kwok, A.K., Ly, K.S., Pio, B., Wei, J., Desai, P.J., Jiang, W., Nguyen, S., Ling, P., Wilson, S.J., Dunford, P.J., Thurmond, R.L., Lovenberg, T.W., et al., 2005, preparation and biological evaluation of indole, benzimidazole, and thienopyrrole piperazine carboxamides: Potent human histamine H4 antagonists., *J. Med. Chem.*, 48, 2–10.
- Venail, F., Attali, P., Wersinger, E., Gomeni, R., Poli, S., and Schmerber, S., 2018, safety, tolerability, pharmacokinetics and pharmacokinetic-pharmacodynamic modelling of the novel H4 receptor inhibitor SENS-111 using a modified caloric test in healthy subjects., *Br. J. Clin. Pharmacol.*, 84, 1–24.
- Verdonk, M.L., Berdini, V., Hartshorn, M.J., Mooij, W.T.M., Murray, C.W.,

- Taylor, R.D., and Watson, P., 2004, virtual screening using protein-ligand docking: Avoiding artificial enrichment., *J. Chem. Inf. Comput. Sci.*, 44, 1–14.
- Vilar, S., Cozza, G., and Moro, S., 2008, medicinal chemistry and the molecular operating environment (MOE): application of QSAR and molecular docking to drug discovery., *Curr. Top. Med. Chem.*, 8, 1–18.
- Vyas, V.K., Ukawala, R.D., Ghate, M., and Chintha, C., 2012, homology modeling a fast tool for drug discovery: current perspectives., *Indian J. Pharm. Sci.*, 1, 1–17.
- Watanabe, A., Nakajima, A., and Shiroishi, M., 2023, Recovery of the histamine H3 receptor activity lost in yeast cells through error-prone PCR and in vivo selection, *Sci. Rep.*, 13, 1–12.
- Watanabe, M., Kobayashi, T., Ito, Y., Fukuda, H., and Yamada, S., 2018, design and synthesis of histamine H3 / H4 receptor ligands with a cyclopropane scaffold., *Bioorg. Med. Chem. Lett.*, 28, 1–4.
- Waters, R. and Urquhart, L., 2019, evaluate pharma world preview 2019., United States.
- Werfel, T., Layton, G., Yeadon, M., Whitlock, L., Osterloh, I., Jimenez, P., Liu, W., Lynch, V., Asher, A., Tsianakas, A., and Purkins, L., 2018, efficacy and safety of the histamine H 4 receptor antagonist ZPL-3893787 in patients with atopic dermatitis., *J. Allergy Clin. Immunol.*, 143, 1–12.
- Worm, J., Falkenberg, K., and Olesen, J., 2019, histamine and migraine revisited: mechanisms and possible drug targets., *J. Headache Pain*, 20, 1–12.
- Wu, A.Z., Lin, C.Z., Zhai, Y.J., Zhuo, J.L., and Zhu, C.C., 2013, investigation of the interaction between two phenylethanoid glycosides and bovine serum albumin by spectroscopic methods., *J. Pharm. Anal.*, 3, 1–5.
- Wu, F., Zhou, Y., Li, L., Shen, X., Chen, G., Wang, X., Liang, X., Tan, M., and Huang, Z., 2020, Computational Approaches in Preclinical Studies on Drug Discovery and Development, *Front. Chem.*, 8, .
- Yamauchi, K. and Ogasawara, M., 2019, the role of histamine in the pathophysiology of asthma and the clinical efficacy of antihistamines in asthma therapy., *Int. J. Mol. Sci.*, 20, 1–16.
- Zeng, Z., Shen, L., Li, X., Luo, T., Wei, X., Zhang, J., Cao, S., Huang, X., Fukushima, Y., Bin, J., Kitakaze, M., Xu, D., and Liao, Y., 2014, disruption of histamine H2 receptor slows heart failure progression through reducing myocardial apoptosis and fibrosis., *Clin. Sci.*, 127, 1–18.
- Zhang, J., Qi, T., and Wei, J., 2012, Homology Modeling and Antagonist Binding Site Study of the Human Histamine H2 Receptor, *Med. Chem. (Los. Angeles)*, 8, 1084–1092.
- Zhou, P., Homberg, J.R., Fang, Q., Wang, J., Li, W., Meng, X., Shen, J., Luan, Y., Liao, P., Swaab, D.F., Shan, L., and Liu, C., 2019, histamine-4 receptor antagonist JNJ7777120 inhibits pro-inflammatory microglia and prevents the progression of Parkinson-like pathology and behaviour in a rat model., *Brain. Behav. Immun.*, 76, 1–13.